FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1608548877> ?p ?o ?g. }

• W1608548877 endingPage "13" @default.
• W1608548877 startingPage "6" @default.
• W1608548877 abstract "Although blood transfusions are essential for patients with hemoglobinopathies (ie Thalassemia, Sickle Cell Disease) or with rare anemias (ie Fanconi, Blackfan Diamond, PK deficiency), chronic transfusions inevitably lead to iron overload as humans cannot actively remove excess iron. The cumulative effects of iron overload lead to significant morbidity and mortality, if untreated. Desferrioxamine (DFO) is the reference-standard iron chelator whose safety and efficacy profile has been established through many years of clinical use. DFO side effects are accettable and manageable however the prolonged subcutaneous infusion regimen of 5-7 days per week is very demanding and results in poor adherence to therapy. Deferiprone (Ferriprox, L1) is a bidentate molecule, orally administrable three-times/day, licensed in Europe and in other regions but in the USA and Canada, for the treatment of iron overload in patients for whom DFO therapy is contraindicated or inadequate. Preliminary evidences suggest that deferiprone may be more effective than DFO in chelating cardiac iron. The side effects include gastrointestinal symptoms, liver dysfunction, joint pain, neutropenia and agranulocytosis. A weekly assessment of white blood cell counts is recommended because of the risk of agranulocytosis. Deferasirox is a new, convenient, once-daily oral iron chelator that has demonstrated in various clinical trials good efficacy and acceptable safety profile in adult and pediatric patients affected by transfusion-dependent thalassemia major and by different chronic anemias (SCD, BDA, MDS). The long half-life of deferasirox (16-18 hours) provides sustained 24 hr iron chelation coverage. The efficacy and safety profile have been evaluated in more than 3000 patients in clinical trials. Patient satisfaction with deferasirox was superior than with DFO therapy." @default.
• W1608548877 created "2016-06-24" @default.
• W1608548877 creator A5007430894 @default.
• W1608548877 creator A5007753770 @default.
• W1608548877 creator A5050350249 @default.
• W1608548877 creator A5078700265 @default.
• W1608548877 creator A5091808347 @default.
• W1608548877 date "2009-06-23" @default.
• W1608548877 modified "2023-09-23" @default.
• W1608548877 title "Progress in the management of iron overload in erytrocyte disorders" @default.
• W1608548877 cites W146649955 @default.
• W1608548877 cites W1534008913 @default.
• W1608548877 cites W158899810 @default.
• W1608548877 cites W1788148082 @default.
• W1608548877 cites W1995812599 @default.
• W1608548877 cites W2014978771 @default.
• W1608548877 cites W2031179986 @default.
• W1608548877 cites W2047446466 @default.
• W1608548877 cites W2054689553 @default.
• W1608548877 cites W2061877805 @default.
• W1608548877 cites W2067697375 @default.
• W1608548877 cites W2069553612 @default.
• W1608548877 cites W2078904403 @default.
• W1608548877 cites W2093543587 @default.
• W1608548877 cites W2094357790 @default.
• W1608548877 cites W2103778162 @default.
• W1608548877 cites W2119692077 @default.
• W1608548877 cites W2120041716 @default.
• W1608548877 cites W2137723066 @default.
• W1608548877 cites W2141728976 @default.
• W1608548877 cites W2156237444 @default.
• W1608548877 cites W2168793485 @default.
• W1608548877 cites W2186837499 @default.
• W1608548877 cites W2317072972 @default.
• W1608548877 cites W2337170605 @default.
• W1608548877 cites W2340473515 @default.
• W1608548877 cites W295614617 @default.
• W1608548877 doi "https://doi.org/10.4081/hmr.v2i5.719" @default.
• W1608548877 hasPublicationYear "2009" @default.
• W1608548877 type Work @default.
• W1608548877 sameAs 1608548877 @default.
• W1608548877 citedByCount "1" @default.
• W1608548877 countsByYear W16085488772020 @default.
• W1608548877 crossrefType "journal-article" @default.
• W1608548877 hasAuthorship W1608548877A5007430894 @default.
• W1608548877 hasAuthorship W1608548877A5007753770 @default.
• W1608548877 hasAuthorship W1608548877A5050350249 @default.
• W1608548877 hasAuthorship W1608548877A5078700265 @default.
• W1608548877 hasAuthorship W1608548877A5091808347 @default.
• W1608548877 hasConcept C126322002 @default.
• W1608548877 hasConcept C187212893 @default.
• W1608548877 hasConcept C2776517179 @default.
• W1608548877 hasConcept C2776672577 @default.
• W1608548877 hasConcept C2777063308 @default.
• W1608548877 hasConcept C2777218474 @default.
• W1608548877 hasConcept C2777799968 @default.
• W1608548877 hasConcept C2777940137 @default.
• W1608548877 hasConcept C2778248108 @default.
• W1608548877 hasConcept C2780014101 @default.
• W1608548877 hasConcept C2781053155 @default.
• W1608548877 hasConcept C2781413609 @default.
• W1608548877 hasConcept C29730261 @default.
• W1608548877 hasConcept C71924100 @default.
• W1608548877 hasConceptScore W1608548877C126322002 @default.
• W1608548877 hasConceptScore W1608548877C187212893 @default.
• W1608548877 hasConceptScore W1608548877C2776517179 @default.
• W1608548877 hasConceptScore W1608548877C2776672577 @default.
• W1608548877 hasConceptScore W1608548877C2777063308 @default.
• W1608548877 hasConceptScore W1608548877C2777218474 @default.
• W1608548877 hasConceptScore W1608548877C2777799968 @default.
• W1608548877 hasConceptScore W1608548877C2777940137 @default.
• W1608548877 hasConceptScore W1608548877C2778248108 @default.
• W1608548877 hasConceptScore W1608548877C2780014101 @default.
• W1608548877 hasConceptScore W1608548877C2781053155 @default.
• W1608548877 hasConceptScore W1608548877C2781413609 @default.
• W1608548877 hasConceptScore W1608548877C29730261 @default.
• W1608548877 hasConceptScore W1608548877C71924100 @default.
• W1608548877 hasIssue "5" @default.
• W1608548877 hasLocation W16085488771 @default.
• W1608548877 hasOpenAccess W1608548877 @default.
• W1608548877 hasPrimaryLocation W16085488771 @default.
• W1608548877 hasRelatedWork W1911216300 @default.
• W1608548877 hasRelatedWork W1983607584 @default.
• W1608548877 hasRelatedWork W1993040097 @default.
• W1608548877 hasRelatedWork W2007537333 @default.
• W1608548877 hasRelatedWork W2018131656 @default.
• W1608548877 hasRelatedWork W2026288205 @default.
• W1608548877 hasRelatedWork W2048748570 @default.
• W1608548877 hasRelatedWork W2056337888 @default.
• W1608548877 hasRelatedWork W2073806216 @default.
• W1608548877 hasRelatedWork W2099316283 @default.
• W1608548877 hasRelatedWork W2103031455 @default.
• W1608548877 hasRelatedWork W2113913489 @default.
• W1608548877 hasRelatedWork W2121230873 @default.
• W1608548877 hasRelatedWork W2150640700 @default.
• W1608548877 hasRelatedWork W2364511414 @default.
• W1608548877 hasRelatedWork W2800765966 @default.
• W1608548877 hasRelatedWork W3036602249 @default.

• next